LISATA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
LISATA THERAPEUTICS, INC. (LSTA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 111.40 thousand shares for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2025-11-06
- LISATA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- LISATA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-06-30 was 0.00 shares.
- LISATA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-03-31 was 111.40K shares, a 15.97% decline year-over-year.
- LISATA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2024-09-30 was 3.90K shares, a 32.76% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month |
|---|---|---|---|
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 0.00 shares derived: sum of 2 quarters · filed 2025-11-06 | 111.40K shares 10-Q · filed 2025-11-06 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 111.40K shares 10-Q · filed 2025-08-07 | |
| 2025-03-31 | 111.40K shares 10-Q · filed 2025-05-08 | ||
| 2024-09-30 | 3.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 3.90K shares derived: sum of 2 quarters · filed 2024-11-12 | 136.47K shares 10-Q · filed 2024-11-12 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 132.57K shares 10-Q · filed 2024-08-12 | |
| 2024-03-31 | 132.57K shares 10-Q · filed 2024-05-09 | ||
| 2023-09-30 | 5.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 77.05K shares derived: sum of 2 quarters · filed 2023-11-02 | 180.90K shares 10-Q · filed 2023-11-02 |
| 2023-06-30 | 71.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 175.10K shares 10-Q · filed 2023-08-14 | |
| 2023-03-31 | 103.85K shares 10-Q · filed 2023-05-09 | ||
| 2022-09-30 | -510.14K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -503.14K shares derived: sum of 2 quarters · filed 2022-11-10 | 37.46K shares 10-Q · filed 2022-11-10 |
| 2022-06-30 | 7.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 547.60K shares 10-Q · filed 2022-08-04 | |
| 2022-03-31 | 540.60K shares 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| BIOVIE INC. (BIVI) | United States | $0.012B |